Dr. William Gradishar

0:02:09

Dr. William Gradishar on Updates in NCCN Breast Cancer Guidelines

0:02:06

Dr. Gradishar on Personalized Treatment in Breast Cancer

0:02:55

HER2 Biosimilars in Clinical Practice - An Interview with Dr. William Gradishar

0:05:15

Mechanisms and Implications of HER2 Resistance - An Interview with Dr. William Gradishar

0:03:01

HER2 Biosimilars in Clinical Practice - An Interview with Dr. William Gradishar.mp4

0:04:42

Patient Success Stories: Hormone Receptor-Positive Metastatic Breast Cancer, William Gradishar MD

0:05:21

Mechanisms and Implications of HER2 Resistance - An Interview with Dr. William Gradishar.mp4

0:00:50

Dr. Gradishar Discusses Dual HER2-Targeting in Breast Cancer

0:04:45

William J. Gradishar - Pathology

0:02:04

Dr. Gradishar on Using Genetic Testing to Identify Actionable Results in Breast Cancer

0:00:52

Dr. Gradishar on the Role of Neratinib in the Treatment of HER2+ Breast Cancer

0:03:24

Assay for Ductal Carcinoma In Situ

0:01:44

Dr. Gradishar Discusses the Treatment of HER2+ Breast Cancer

0:01:49

Dr. Gradishar on Selecting Agents for HER2+ Breast Cancer

0:20:13

Advanced Hormone Receptor-positive Breast Cancer

0:08:41

New biomarker with potential to help gbm patients with Amy Heimberger, MD, & William Gradishar, MD

0:24:19

SABCS 2017 roundtable with Dr. Hope S. Rugo and Dr. William J. Gradishar

0:02:23

Clinical Trials and Advances in Breast Cancer Therapy at Northwestern Medicine

0:03:23

Woman In Chicago With Breast Cancer Survives And Also Becomes A Mom

0:05:17

Hope and Progress for the Future of Breast Cancer Treatment

0:05:50

Anastrazole and Fulvestrant in Hormone Receptor-Positive Breast Cancer

0:55:48

New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Bagegni & Dr. Gradishar

0:02:50

An Overview of Immunotherapy in Breast Cancer

0:03:49

CDK Inhibitors - Comparative Efficacy